
|Articles|October 6, 2017
Ophthalmology Times Bausch & Lomb Partner Perspective
Advertisement
Partner Perspectives
What is this?
×
Partner Perspectives allows marketers to connect directly with the Ophthalmology Times audience by enabling them to share their content. This content does not necessarily reflect the views of Ophthalmology Times editorial staff or UBM.
Learn more
Become a partner
PROLENSA® (bromfenac ophthalmic solution) 0.07%
Please see Indication and Important Safety Information for PROLENSA® on video.
Contact us: In order to provide more personalized service, we ask that you report any concerns with Bausch + Lomb Products via phone at 800-553-5340.
Product Concerns: 800-553-5340
Order Inquiries for professionals: 800-828-9030
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
3
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
4
Sandoz Canada launches aflibercept biosimilar, Enzeevum
5




























